Who is sponsoring NCT04284657?

NCT04284657 is sponsored by University of Southern California.

What drugs are being tested in NCT04284657?

Interventions in NCT04284657: Pravastatin, sodium citrate.

What condition does NCT04284657 study?

NCT04284657 studies Autosomal Dominant Polycystic Kidney Disease.

Is NCT04284657 still recruiting?

NCT04284657 is currently completed. Last updated 6 August 2025.

Last reviewed 2025-08-06 · How we verify

NCT04284657: ADPKD-SAT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pravastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease

Completed Phase 2 Last updated 6 August 2025

What this trial tests

Phase 2 trial testing Pravastatin in Autosomal Dominant Polycystic Kidney Disease in 1 participant. Completed in 4 August 2025.

Timeline

30 January 2019

Primary endpoint
4 August 2025

4 August 2025

Quick facts

Lead sponsor	University of Southern California
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	1
Start date	30 January 2019
Primary completion	4 August 2025
Estimated completion	4 August 2025
Sites	1 location across United States

Drugs / interventions tested

Pravastatin — full drug profile →
sodium citrate (SODIUM CITRATE) — full drug profile →

Conditions studied

Autosomal Dominant Polycystic Kidney Disease — all drugs for Autosomal Dominant Polycystic Kidney Disease →

Sponsor

University of Southern California

Who can join

18 and older, any sex, with Autosomal Dominant Polycystic Kidney Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an one-year open-label study to determine treatment efficacy and feasibility of a trial that uses open-label interventions in ADPKD patients.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Experimental Models of Polycystic Kidney Disease: Applications and Therapeutic Testing.
Sieben CJ, Harris PC. · · 2023 · cited 23× · PMID 37418622 · DOI 10.34067/kid.0000000000000209
Targeting and therapeutic peptide-based strategies for polycystic kidney disease.
Wang J, Tripathy N, Chung EJ. · · 2020 · cited 14× · PMID 32866560 · DOI 10.1016/j.addr.2020.08.011
Prioritized polycystic kidney disease drug targets and repurposing candidates from pre-cystic and cystic mouse Pkd2 model gene expression reversion.
Wilk EJ, Howton TC, Fisher JL, Oza VH, et al · · 2023 · cited 6× · PMID 37217845 · DOI 10.1186/s10020-023-00664-z
The risk of CKD progression remains high in patients treated with ACE inhibitors and ARBs, MRAs and SGLT2 inhibitors. Have we already achieved the therapeutic ceiling in CKD? (The CON part)
· 2024

Verify or expand the search:

Other trials of Pravastatin

Trials testing the same drug.

NCT06494111 — Systemic Therapy of Open-label Prophylactic Pravastatin or Pentoxifylline/Tocopherol Prevention of Lymphedema Advancing · Phase 2 · recruiting
NCT05852769 — A Study to Evaluate the Drug-drug Interaction Potential of BMS-986196 in Healthy Participants · Phase 1 · completed
NCT05524246 — Pravastatin as a Prophylactic to Reduce Endothelial Injury in Pediatric Patients With Elevated Body Mass Index · Phase 1 · completed
NCT04608344 — Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filg · Phase 1 · completed
NCT04190433 — Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial · Phase 2 · withdrawn

Other recruiting trials for Autosomal Dominant Polycystic Kidney Disease

Currently open trials in the same condition.

NCT07228364 — Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease · Phase 1 · recruiting
NCT07217158 — Role of ROS and cAMP-PKA Biomarkers in ADPKD · active not recruiting
NCT06065852 — National Registry of Rare Kidney Diseases · recruiting

Other University of Southern California trials

Trials by the same sponsor.

NCT07288463 — Hearing Loss and Genetic Risks for Alzheimer's Disease and Related Dementia · NA · not yet recruiting
NCT05914233 — Non-invasive Ultrasound Retinal Stimulation for Vision Restoration · NA · not yet recruiting
NCT06163664 — Role of ChatGPT in Vestibular Schwannoma Management · NA · withdrawn
NCT07332312 — A Culturally Informed Patient Navigation Program (CFPN) to Reduce Delays Between Diagnosis and Treatment in American Ind · NA · not yet recruiting
NCT07290478 — Encouraging Older Adults and Adults With Serious Illness to Designate a Health Care Proxy · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04284657 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Southern California
Last refreshed: 6 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04284657.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing